Longitudinal Communication Outcomes Following Traumatic Brain Injury
Funder
National Health and Medical Research Council
Funding Amount
$798,171.00
Summary
Traumatic brain injury (TBI) is the leading cause of disability in young Australians. The condition frequently manifests in impaired verbal communication. Communication is essential to successful rehabilitation, and return to society. However, the critical time for delivery of optimal treatment for communication remains unknown. This prospective longitudinal study will examine communication recovery following (TBI) to identify predictors of recovery and the best time to offer treatment.
Premature Mortality Post Fracture:A NSW Linked Data Study
Funder
National Health and Medical Research Council
Funding Amount
$391,012.00
Summary
Osteoporotic fractures are associated with increased morbidity and mortality. Anti-osteoporosis medications reduce re-fracture and possibly morality, yet osteoporosis is poorly treated. This study will link information from >260,000 people (45&Up study) with hospital admissions, medications and deaths to create the largest, detailed dataset of its kind. We will be able to determine cause of any fracture-associated mortality and the effect of medication to improve osteoporosis management.
Perinatal Stress Leads To Neurosteroid Deficits And Adverse Behavioural Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$1,198,042.00
Summary
This grant will examine the effect of psychosocial stress experienced after birth on the production and regulation of steroid hormones in the brain of newborn animals. The work will investigate how stress changes the levels these brain steroids and sensitivity to them and if these effects are remain into adulthood. The studies will then determine if these changes lead to adolescent behaviour disorders. The effectiveness of steroid therapies in treating these disorders will also be determined.
Helping Stroke Physicians Choose Who To Thrombolyse - The Targeting Optimal Thrombolysis Outcomes (TOTO) Study
Funder
National Health and Medical Research Council
Funding Amount
$1,073,140.00
Summary
Thrombolysis using alteplase is one of the most effective treatments for stroke but is currently used in only 5% of stroke cases. A major barrier is a lack of tools to identify who will benefit from treatment, or who might have a major adverse event. In this study we will develop a clinical decision rule based on clinical data, advanced CT imaging, and blood biomarkers to help identify those who will benefit and those likely to bleed, to encourage wider use of this treatment in acute stroke.
Fetal Sex: An Important Determinant Of The Placental Transcriptome
Funder
National Health and Medical Research Council
Funding Amount
$553,574.00
Summary
There are fetal sex differences in pregnancy outcomes that place boys at greater risk than girls. These are likely caused by genetic differences in the placenta. We will use 21st century gene sequencing technology to obtain the complete sequence of placental genes in early pregnancy and normal term placenta to determine what the genetic differences are between male and female placentas. This may be important in developing future sex specific therapeutics for babies in the neonatal nursery.
A Randomized Controlled Trial Of Effects Of Early Life Exposure To General Anaesthesia On Neurobehavioural Outcomes In Children With Cystic Fibrosis (CF)
Funder
National Health and Medical Research Council
Funding Amount
$587,240.00
Summary
Anaesthesia permits surgeries and other interventional procedures that benefit the health of children to be performed painlessly and non-traumatically. This study will provide critical information about whether the drugs used commonly for general anaesthesia represents a risk to very young children in terms of their neurobehavioural development.
Fundamental flaws in the design and reporting of research outcomes can undermine evidence-based medicine, impede patient-centred care, cause harm to patients, and result in a waste of research dollars. Our 3-year multinational project engages with patients, caregivers, clinicians, researchers and policy makers, to establish core outcomes in haemodialysis. This will ensure that patient-centred outcomes are consistently measured and reported in haemodialysis trials and other forms of research.
Clinical And Psychosocial Changes Over Late Childhood And Adolescence And Early Life Determinants Of Long Term Clinical Outcomes In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$1,135,570.00
Summary
Cystic fibrosis is the most common life shortening inherited disease in Caucasians. Lung damage starts in infancy and lung function falls most rapidly in adolescence although why and how this happens and early life determinants are not known. This study takes advantage of a previous study that monitored young children from 3 months to 5 years of life and follows them closely through early adolescence to investigate the protective and risk factors for falling lung function.
Is Placental Aging The Key To Understanding, Predicting And Preventing Stillbirth?
Funder
National Health and Medical Research Council
Funding Amount
$473,861.00
Summary
Stillbirth occurs in 35 times as many pregnancies as sudden infant death but the causes are unknown. This project will help to develop tests that can predict the risk of stillbirth so that the obstetrician can deliver the baby before it dies. The investigators hypothesise that stillbirth is due to aging of the placenta and that markers of the aging placenta can be detected in the mother’s blood. The project brings together experts in the placenta, aging and obstetric care of high risk pregnancy.
Post-stroke Hyperglycaemia – Treatment With Exenatide In Acute Ischaemic Stroke (TEXAIS) Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,266,149.00
Summary
Raised blood glucose levels (hyperglycaemia) after a stroke is common. It reduces the efficacy of stroke treatments and results in worse outcomes. Insulin is not useful as a treatment for this as it causes frequent hypoglycaemia and does not improve clinical outcomes. Exenatide is a common diabetes drug that is simple to use and lowers blood glucose without hypoglycaemia. It will be tested in the Treatment with Exenatide in Acute Ischaemic Stroke (TEXAIS) trial.